← All indications
Myositis
Inflammation of a muscle or muscle tissue.
Subtype terms (5)
More specific conditions that are subtypes of Myositis in the MeSH hierarchy.
- Myositis, Inclusion Body
16 drugs (9 approved, 7 experimental)
- Myositis Ossificans
7 drugs (2 approved, 5 experimental)
- Orbital Myositis
- Polymyositis
31 drugs (20 approved, 11 experimental)
- Pyomyositis
2 drugs approved
Drugs by status
Phase 4 trials (3)
Phase 3 trials (14)
Phase 2 trials (19)
Phase 1 trials (31)
- bendamustine
- celecoxib
- natalizumab
- pioglitazone
- igm-2323
- cemdisiran
- allogeneic gamma-delta t cells
- 68ga-fapi
- cc-97540
- ct-rd06
- pozelimab
- gc012f
- cd19 car-nk cells
- clbr001
- swi019
- equecabtagene autoleucel
- kite-363
- cnty-101
- cd19-car-dnt cells
- ctx112
- ucar-t cells
- cc312
- impt-514
- kyv-101
- azd5492
- rd06-05
- hbi0101 cart
- ol-108
- utaa91
- allo-329
- +1 more
Organizations
Organization Involved with Phase 3 Indications (16)
- Bristol-Myers Squibb
- Schering-Plough
- Novartis
- GlaxoSmithKline
- Orphazyme
- Medical Research Council
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- University of London
- Harvard University
- Institut National de la Santé Et de la Recherche Médicale, France
- Northwell Health
- University of East Anglia
- University of Kansas
- Kwong Wah Hospital
- Karolinska Institute
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (18)
- PPD
- Regeneron
- Roche
- Eli Lilly
- Genentech
- MedImmune
- Biogen
- The Heartbeat Trust
- National Institute of Environmental Health Sciences (NIEHS)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pittsburgh
- University of Manchester
- Western Michigan University
- Mayo Clinic
- Peking University
- University of Paris
- National University of Ireland
- St Vincent's University Hospital, Ireland
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (4)